ABEMACICLIB 150 mg (Ramiven) x 14 Tablets

Uses of ABEMACICLIB 150 mg

• Treats hormone receptor-positive (HR+), HER2-negative breast cancer.
• Used in advanced or metastatic breast cancer.
• Used in combination with hormonal therapy (like letrozole or fulvestrant).
• Used as adjuvant therapy in early breast cancer at high risk of recurrence.

Benefits of ABEMACICLIB 150 mg

• Slows growth of cancer cells.
• Helps delay disease progression.
• Improves response to hormone therapy.
• Reduces risk of cancer recurrence.
• Oral targeted therapy option.

How does it work?

Abemaciclib is a CDK4/6 inhibitor. It blocks cyclin-dependent kinases (CDK4 and CDK6), which are proteins that help cancer cells divide. By stopping these signals, it prevents cancer cells from multiplying.

Precautions

• Take exactly as prescribed, with or without food.
• Take at the same time each day.
• Regular blood count and liver function tests are required.
• Inform your doctor about diarrhea (common side effect).
• Stay well hydrated, especially if diarrhea occurs.
• Tell your doctor about all medicines you are taking.
• Avoid pregnancy during treatment.
• Report severe weakness, fever, or signs of infection immediately.

Side Effects

• Diarrhea
• Fatigue
• Nausea
• Low white blood cell count

Get Abemaciclib 150mg (Ramiven) Tablets at competitive prices from our generic pharmacy

We supply high‑quality Abemaciclib 150 mg (Ramiven) Tablets, a trusted therapy used to effectively treat HR-positive, HER2-negative advanced or metastatic breast cancer.

As a leading pharmaceutical wholesaler, we deliver generic oncology medications to patients, hospitals, physicians, clinics, and healthcare centers in international markets, including Colombia, Peru, the Philippines, Venezuela, Panama, Ecuador, Namibia, South Africa, Zimbabwe, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Palestine, Qatar, Saudi Arabia, the United Arab Emirates, China, Canada, Brazil, Mexico, Russia, Thailand, Malaysia, Singapore, Vietnam, South Korea, Taiwan, Indonesia, the United States, and more.